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Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019  
Covid-19.
It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, 
might represent a target for decreasing the risk of the acute respiratory complications of the COVID-
19 infection but 1) lack of demonstration of SARS-CoV2 binding to DPP4 2) possible protective role 
of sDPP4 in Middle East respiratory Syndrome (MERS-CoV 3) demonstrated inhibition and 
downregulation of DPP4 by HIV1 and MERS-CoV and 4) not exclusive role of the receptor binding in 
tropism of the Coronavirus family, support that DPP4 inhibition at present doesn’t represent a 
plausible approach to mitigate Covid-19.
The rapid spread of the coronavirus disease 2019 (Covid-19), caused by a zoonotic beta-
coronavirus entitled SARS-CoV2, has become a global threat.  According to a meta-analysis of 76993 
patients presented in 10 articles, the prevalence of diabetes among people who were infected with 
SARS-CoV2 was estimated to be 7,9%1. Diabetes could be a risk factor for severity and mortality in 
patients with Covid-19. A study, which included 72.314 cases of Covid-19, demonstrated that 
diabetic subjects had a threefold higher mortality rate than did those without diabetes (7.3% vs 2.3 
%)2.
A recent commentary on Diabetes Research and Clinical Practice described the interplay between 
the Middle East Respiratory Syndrome (MERS-CoV), another coronavirus responsible for an 
outbreak of acute respiratory syndrome, and human dipeptidyl peptidase 4 (DPP4) identified as a 
functional receptor for virus spike protein3. It has been interestingly hypothesized that DPP4 
inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing 
2the risk of the acute respiratory complications of the COVID-19, but, unfortunately, this hypothesis 
is on the basis of another hypothesis. To the best of our knowledge, no one has yet shown that DPP4 
is a possible receptor for SARS-COV2. On the contrary most recent data exclude this possibility, 
confirming that human angiotensin-converting enzyme 2 (ACE2) is the receptor for SARS-CoV2, in 
analogy to SARS-CoV4. 
DPP4, like the ancient roman god Janus Bifrons (Two-Faced), is a dual and multifunctional molecule: 
it exists as soluble form (sDPP4) in the circulation5, but also as a type II transmembrane glycoprotein 
located on endothelial, epithelial cells and immune cells (CD26)6. DPP4 in the bloodstream and at 
surface membrane rapidly inactivates biologically active molecules as gastrointestinal hormones, 
neuropeptides and chemokines, but in some cases shifts their receptor preference and thus 
modifies their functional activity. In addition to enzymatic cleavage, CD26 executes other multiple 
physiological mechanisms, as adhesion to extracellular matrix proteins, and it plays a co-stimulatory 
role in T-cell maturation, activation and interaction with antigen-presenting cells. Thus, DPP4 
inhibition is associated with some degree of immune suppression and may be useful in some 
autoimmune diseases7. However, in most patients long-term immune suppression, albeit mild, 
could represent an undesirable side effect8. We described a case of a type 2 diabetes subject with a 
severe leucopenia as a consequence of DPP4 inhibitor Sitagliptin therapy9. In diabetic subjects 
treated with DPP4 inhibitors there is no increase in respiratory tract infections10, but we want to 
highlight that they could produce respiratory side effects as angioedema11, rhinorrhea12, cough and 
dyspnea13, as consequences of reduced degradation of bradykinin and substance P.
MERS is another example of DPP4 ambivalence. As expected, human DPP4 transgenic mice following 
MERS-CoV infection develop an acute inflammatory response of the lung with progressive 
pulmonary fibrosis14. However hDPP4+/+ mice were more resistant than hDPP4+/− mice to MERS-
CoV infection, as judged from increased LD50, reduced lung viral infection, attenuated morbidity 
and mortality, and reduced histopathology15. A possible explanation of this paradoxical protective 
effect of DPP4 against MERS-CoV is that the soluble DPP4 can act as a “buffer” competitively 
inhibiting virus entry into host cells. In fact, in human patients affected by MERS there is a reduction 
in circulating levels of sDDP4 with an inverse relationship with IL-10 level. In support of an antiviral 
effect of sDPP4, the authors demonstrated that viral infection was inhibited by 50% in the presence 
of more than 8000 ng/ml of sDPP416. Another aspect to consider is the possibility that MERS-CoV 
downregulates its receptor after the binding: dromedaries with experimental MERS show reduction 
of the cell surface receptor dipeptidyl peptidase17. Likewise, downregulation of ACE2 receptor has 
3been already demonstrated for SARS-CoV and SARS-CoV218. Furthermore, the Human Deficiency 
Virus 1 (HIV1) uses DPP4 as a receptor; HIV-infected cells produce TAT proteins that inhibit DPP4 
activity inducing a decrease of responsiveness of human peripheral T cells19.
Finally, virus tropism is a complex phenomenon. In the case of the Coronavirus family, while 
understanding the expression pattern of the receptor can define which cells can be infected, it does 
not mean all cells that express the receptor or even the cells with the highest expression are the 
major targets. In the case of ACE2 the human lung is the 22th tissue for the amount of receptors20. 
Probably is not only the spike protein that impacts on tissue tropism; other “background genes,” 
including nucleocapsid, replicase and accessory genes, are also important determinants of tropism.
In conclusion, 1) lack of demonstration of SARS-CoV2 binding to DPP4 2) possible protective role of 
sDPP4 in MERS 3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and 
4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 
inhibition does not represent a plausible approach to mitigate Covid-19.
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